BREZTRI approved in the US for asthma as first and only triple therapy for patients 12 years of age and older

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. DFTX
7. GOOGL
8. MU
9. IBM
10. HOOD

Go back to BREZTRI approved in the US for asthma as first and only triple therapy for patients 12 years of age and older

AstraZeneca Q1 preview: In-line quarter expected as pipeline catalysts take center stage

April 28, 2026 4:00 PM EDT

AstraZeneca (NASDAQ: AZN) reports first-quarter results on Wednesday, with analysts expecting a solid but unexciting print, as investor focus shifts firmly toward a busy second-half pipeline newsflow that Bank of America says could drive a meaningful re-rating of the stock.

BofA analyst Sachin Jain said in a preview note released at the start of April... More